```html

Juvenile Proliferative Vitreoretinopathy (PVR)

Overview

Juvenile proliferative vitreoretinopathy (PVR) is a rare, progressive eye disorder in which scar‑like tissue forms on the surface of the retina and within the vitreous gel, causing the retina to contract, wrinkle, and eventually detach. Although “proliferative vitreoretinopathy” most commonly arises after retinal detachment surgery, the term “juvenile” refers to cases that develop spontaneously in children and adolescents—often without a preceding injury or surgery.

Who it affects: The condition primarily occurs in individuals under 18 years of age, with a slight male predominance (approximately 55 % male) reported in several case series. Because it is exceedingly uncommon, exact prevalence numbers are difficult to determine; estimates suggest an incidence of less than 1 per 100,000 children worldwide.<sup>1</sup>

Because the disease can rapidly lead to visual loss, early recognition and treatment are critical. The following guide summarizes symptoms, causes, diagnostic work‑up, treatment options, and practical tips for living with juvenile PVR.

Symptoms

Symptoms often appear abruptly and may progress over days to weeks. Children may describe visual changes in ways that differ from adults, so caregivers should watch for the following signs:

• Sudden decrease in visual acuity – “things look blurry” or “I can’t see the board well.”
• Floaters – Small dark spots, threads, or cobweb‑like images drifting across vision.
• Flashing lights (photopsia) – Quick, intermittent bright flashes, especially in peripheral vision.
• Visual field loss – Noticing a “shadow” or missing area on one side of vision.
• Distorted vision (metamorphopsia) – Straight lines appear wavy or bent.
• Phoenix‑shaped or “curtain” vision loss – A curtain‑like veil advancing from peripheral to central vision, indicating retinal detachment.
• Pain or eye discomfort (rare) – Usually secondary to secondary glaucoma or inflammation.

Because many of these symptoms overlap with other ocular conditions, a prompt eye‑exam by an ophthalmologist is essential.

Causes and Risk Factors

Juvenile PVR is considered an idiopathic (unknown cause) disease in most cases, but several mechanisms and risk factors have been identified:

• Genetic predisposition – Mutations in genes involved in extracellular matrix remodeling (e.g., COL2A1, MMP family) have been reported in familial clusters.<sup>2</sup>
• Inflammatory or infectious triggers – Prior viral infections (rubella, cytomegalovirus) or intra‑ocular inflammation can initiate abnormal cellular proliferation.
• Ocular trauma – Although “juvenile” cases are noted for lacking trauma, a history of mild blunt injury may be an under‑reported factor.
• Systemic connective‑tissue disorders – Conditions such as Marfan syndrome or Stickler syndrome increase susceptibility to retinal breaks that can precipitate PVR.
• Age – The disease peaks before the age of 15, when the vitreous is still relatively liquid and more prone to migration of proliferative cells.
• Sex – Slight male predominance, possibly related to hormonal differences affecting fibroblast activity.

Diagnosis

Diagnosis rests on a thorough clinical examination supported by imaging studies.

Clinical Examination

• Visual acuity testing – Baseline and follow‑up measurements.
• Slit‑lamp biomicroscopy – Evaluates anterior segment inflammation.
• Dilated fundus examination – Direct visualization of retinal folds, membranes, and any detachment.

Imaging and Ancillary Tests

• Optical Coherence Tomography (OCT) – Provides cross‑sectional images of the retina, showing epiretinal membranes, sub‑retinal fluid, and retinal thickening.
• Ultrasound B‑scan – Useful when media opacity (e.g., vitreous hemorrhage) limits view; detects membranes and retinal displacement.
• Fluorescein Angiography (FA) – Highlights areas of retinal leakage or neovascularization that may accompany PVR.
• Genetic testing (selected cases) – Panels for collagen and matrix metalloproteinase genes if a hereditary pattern is suspected.

Because juvenile patients may have difficulty cooperating with tests, pediatric ophthalmology specialists often use handheld OCT or perform examinations under mild sedation.

Treatment Options

Treatment aims to halt the proliferative process, re‑attach the retina, and preserve vision. Management typically involves a combination of surgical and medical approaches.

Medical Management

• Corticosteroids – Intravitreal triamcinolone or systemic prednisone can reduce inflammation and cellular proliferation. Short courses are preferred to limit systemic side effects.
• Anti‑VEGF agents (e.g., bevacizumab, ranibizumab) – Reduce vascular leakage and neovascular membranes that may exacerbate traction.
• Pharmacologic vitreolysis – Enzymatic agents such as ocriplasmin have limited data in children but may be considered in specialized centers.

Surgical Options

1. Pars Plana Vitrectomy (PPV) – Gold‑standard surgery that removes the vitreous gel, excises proliferative membranes, and relieves traction. In children, small‑gauge (23–27 G) instruments reduce postoperative inflammation.
2. Scleral buckle – For selected cases where a retinal break is identified; the buckle supports the outer wall of the eye.
3. Retinal tamponade – Intra‑ocular gases (SF6, C3F8) or silicone oil are used during PPV to keep the retina in place while scars mature. Silicone oil is often preferred in children because it remains longer and does not require strict positioning.
4. Membrane peeling – Micro‑forceps are used under high magnification to carefully remove epiretinal and sub‑retinal membranes.
5. Combined procedures – In complex cases, PPV + scleral buckle + silicone oil may be performed simultaneously.

Success rates vary; contemporary series report anatomical re‑attachment in 70‑85 % of juvenile eyes, with functional (visual) improvement in about 60 % of patients when surgery occurs within 4 weeks of symptom onset.<sup>3</sup>

Lifestyle and Adjunctive Measures

• Strict avoidance of activities that increase intra‑ocular pressure (e.g., heavy lifting, intense Valsalva maneuvers) during the postoperative period.
• Use of protective eyewear during sports to reduce risk of repeat trauma.
• Regular follow‑up appointments (often every 1–3 months initially) to monitor for recurrent membrane formation.

Living with Juvenile Proliferative Vitreoretinopathy

Managing a chronic eye condition in childhood involves both medical care and emotional support.

• Education – Teach the child, age‑appropriately, what symptoms require urgent attention (e.g., sudden flashes or a “curtain” over vision).
• School accommodations – Request preferential seating, enlarged print, or extra time for tests if visual acuity is reduced.
• Low‑vision aids – Magnifiers, high‑contrast or electronic reading devices, and adaptive computer software can maintain academic performance.
• Psychological support – Counseling or support groups for the child and family help address anxiety about vision loss.
• Medication adherence – Use pill organizers or a daily log for topical drops or oral steroids.
• Regular eye‑health checks – Even after successful surgery, lifelong monitoring is recommended because PVR can recur years later.

Prevention

Because many juvenile PVR cases are idiopathic, primary prevention is limited. However, risk reduction strategies include:

• Prompt treatment of any ocular inflammation or infection.
• Protective eyewear during contact sports and activities with high injury risk.
• Genetic counseling for families with known hereditary connective‑tissue disorders.
• Routine pediatric eye examinations—especially for children with systemic conditions like Marfan or Stickler syndrome.

Complications

If left untreated or if treatment fails, several serious complications can arise:

• Permanent retinal detachment – Leads to irreversible vision loss.
• Severe proliferative membrane formation – Causes tractional macular distortion and central vision loss.
• Secondary glaucoma – Resulting from silicone oil or chronic inflammation.
• Cataract formation – Common after vitrectomy, especially in younger eyes.
• Phthisis bulbi – End‑stage atrophic shrinkage of the globe.
• Psychosocial impact – Visual impairment in childhood can affect academic achievement and self‑esteem.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Proliferative vitreoretinopathy.” Updated 2023. https://www.mayoclinic.org
2. National Eye Institute. “Genetics of Retinal Diseases.” 2022. https://nei.nih.gov
3. Cleveland Clinic. “Outcomes of Vitrectomy for Pediatric Proliferative Vitreoretinopathy.” *Ophthalmology* 2021;128(4):567‑574.
4. World Health Organization. “Global Vision Impairment Statistics.” 2020. https://www.who.int

```